The Financial Horizons
No Result
View All Result
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
  • Latest News
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
  • Latest News
No Result
View All Result
The Financial Horizons
No Result
View All Result
Home Editor's Pick

Royal Bank of Canada stock double-tops ahead of Q1 earnings

by
February 23, 2026
in Editor's Pick
0
Royal Bank of Canada stock double-tops ahead of Q1 earnings
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Royal Bank of Canada stock has been in an unstoppable bull run in the past few years and is now hovering at its all-time high. It has soared by 160% in the last five years, beating JPMorgan, which has jumped by over 133% in the same period. So, will the rally accelerate as the company publishes its results this week?

Royal Bank of Canada stock to react to first-quarter results 

RBC and other Canadian stocks have done well in the past few years. For example, TD Bank stock soared by 110%, while Bank of Montreal soared by over 128% in the last five years. Their performance was much better than the broader TSX Composite, which has jumped by 83% in the same period.

RBC, Canada’s biggest bank, has done better than other companies because of its business model, which includes operations in the United States and other countries.

It is also a major player in areas like wealth management, personal banking, capital markets, commercial banking, and insurance. This diversification helps it to generate substantial non-interest revenue, which is important as interest rates come down.

The most recent results showed that its net income jumped by 25% YoY to over $20.4 billion, making it the most profitable banks in the industry.

Its personal banking revenue jumped by 20%, helped by higher interest rates, while its wealth management rose by 25%. The other top segments, like insurance and capital markets, grew by over 10%, with the latter benefiting from the volatility in the equities, forex, and interest rates trading.

Analysts believe that the company’s revenue and profits did well in the first quarter, helped by the key segments like wealth management and capital markets activity. The average estimate is that its revenue rose by 4.87% in the first quarter to over $17.5 billion. 

Its earnings per share are expected to grow from $3.62 to $3.84. Chances are that its business will be much better than expecte,d as it has always done. Also, most comparable American banks like Morgan Stanley and JPMorgan published modest results.

Analysts also expect that the annual revenue will be $70.4 billion this year, up by 5.75% from what it made last year. It will then make $73 billion next year, with the momentum expected to continue in the future.

Still, the main concern about RBC is that it has become highly expensive. Data shows that it has a trailing price-to-earnings ratio of 18, higher than JPMorgan’s 15 and Bank of America’s 13. Also, its price-to-book multiple of 2.7 is higher than other top banks, while the Bank of Canada has warned about the economy.

RBC stock price technical analysis 

Royal Bank of Canada stock chart | Source: TradingView 

The daily timeframe chart shows that the RBC stock price has been in a strong uptrend in the past few months.

Recently, however, there are signs that the momentum has faded in the past few weeks. It has formed a double-top pattern at $238.23 and a neckline at $224.

The stock has formed a bearish divergence pattern as the MACD indicator has moved downwards and is hovering near the zero line. Also, the Relative Strength Index (RSI) has dropped from the overbought level of 83 to the current 60.

Therefore, the double-top pattern points to a potential downside, in the near term. However, a move above the double-top pattern at $238 will invalidate the double-top pattern and point to more gains, potentially to $250.

The post Royal Bank of Canada stock double-tops ahead of Q1 earnings appeared first on Invezz

Previous Post

Eli Lilly bets on multi-dose Zepbound pen in GLP-1 retention push

Next Post

Merck creates separate oncology arm ahead of Keytruda patent loss

Next Post
Merck creates separate oncology arm ahead of Keytruda patent loss

Merck creates separate oncology arm ahead of Keytruda patent loss

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent News

    SoFi stock price has imploded: will it rebound?

    SoFi stock price has imploded: will it rebound?

    February 23, 2026
    Lucid stock falling wedge pattern points to a surge after earnings

    Lucid stock falling wedge pattern points to a surge after earnings

    February 23, 2026
    Zoom Video stock: Wyckoff Theory points to a 100% surge

    Zoom Video stock: Wyckoff Theory points to a 100% surge

    February 23, 2026
    Why analysts see Alphabet stock surging over 20%

    Why analysts see Alphabet stock surging over 20%

    February 23, 2026
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: Thefinancialhorizons.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
    Copyright © 2026 thefinancialhorizons.com | All Rights Reserved

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Editor’s Pick
    • Latest News

    Disclaimer: Thefinancialhorizons.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
    Copyright © 2026 thefinancialhorizons.com | All Rights Reserved